Teva Pharmaceutical Industries Ltd. has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs. The settlement was disclosed on Tuesday in papers filed in federal court …
Source: Claims Journal